Pediatric secondary CML in a patient with HLH carrying UNC13D , LYST and
Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening
disease. This case report describes a secondary chronic myelogenous
leukemia (CML) in a nine-year-old male after treatment with a
combination of etoposide (VP16), steroids and cyclosporin for HLH. VP16
can potentially induce leukemia, and single nucleotide polymorphisms may
be involved in the pathogenesis of CML. We speculate that genetic
backgrounds combined with chemotherapeutic drugs lead to secondary CML.
This case report alerts physicians to the importance of genetic
screening and the rare side effects of VP16 in children with HLH.